Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Funck | M | 62 | 37 years | |
| Scott House | M | - | 34 years | |
| Adel Moussa | M | - | 22 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Tom R. Hodgson | M | 82 | 12 years | |
| Richard de Schutter | M | 83 |
G.D. Searle & Co., Inc.
 G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | 4 years |
| Elaine R. Leavenworth | F | 65 | 27 years | |
| Daniel P. Getman | M | 68 | - | |
| Dipak Panigrahi | M | - | - | |
| G. Kirk Raab | M | 88 | 4 years | |
| William Ashton | M | 73 | 6 years | |
| Andrew J. Ferrara | M | 84 | 3 years | |
| Peter Lichtlen | M | 56 |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 9 years |
| Wayne T. Hockmeyer | M | 79 | - | |
| Duane L. Burnham | M | 82 | 9 years | |
| H. Fuller | M | 85 | - | |
| Andrew Smith | M | 61 | 6 years | |
| Denise Scots-Knight | M | 64 | 11 years | |
| Steven M. Rauscher | M | 70 | 18 years | |
| James Young | M | - | 33 years | |
| Jack Schuler | M | 83 | 17 years | |
| Mary Szela | F | 60 | 25 years | |
| Thomas Joseph Dee | M | 60 | 23 years | |
| Thomas Knapp | M | 71 | 5 years | |
| Charles W. Cramb | M | 77 | 9 years | |
| David Arkowitz | M | 62 | 4 years | |
| Michael Carter | M | - | - | |
| S. Ken Tanaka | M | 72 | - | |
| Keith Maynard Lingenfelter | M | - | 12 years | |
| Mark McCamish | M | 72 | 7 years | |
| Martin Gertsch | M | 59 |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 2 years |
| David Stamler | M | 63 | 4 years | |
| Douglas Liu | M | 62 | 10 years | |
| John R. Tushar | M | 62 | - | |
| Michael Fiechtner | M | - | 12 years | |
| Michael Williams | M | - | 11 years | |
| Joe R. Sanders | M | - | 10 years | |
| Gary Stevenson | M | - | 7 years | |
| R. James Danehy | M | - | 21 years | |
| Bill Welch | M | 62 | 5 years | |
| Ian McLeod | M | - | 3 years | |
| Matt van Bergen | M | - | 2 years | |
| Brian L. Durkin | M | 63 | 30 years | |
| Sharon Larkin | F | 60 | 23 years | |
| Robert Michael | M | 53 | 19 years | |
| Louise Dube | M | - | 14 years | |
| Karen Peterson | F | - | 30 years | |
| Brian Fenton | M | 57 | 5 years | |
| Keith Pietropaolo | M | - | 11 years | |
| Terry Opgenorth | M | 68 | 20 years | |
| Anthony Barnes | M | 69 | 2 years | |
| Lisa Giles | F | 65 | 10 years | |
| Silvia Taylor | F | - | 6 years | |
| Chris M. Kolber | M | - | 14 years | |
| Christopher Rovaldi | M | 50 | 3 years | |
| Azita Saleki-Gerhardt | M | 60 | 19 years | |
| Corlis D. Murray | F | - | 31 years | |
| Anne Schmidt | M | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
| Cary Claiborne | M | 64 | 3 years | |
| Shawn M. Marcell | M | 62 | 7 years | |
| Fang-Tyan Chen | M | 74 | 22 years | |
| Pamela Thomas-Graham | F | 60 | 5 years | |
| Susan L. Koppy | F | 62 | 1 years | |
| Jean-Yves F. Pavée | M | 60 | - | |
| Carlos Alban | M | 61 | 26 years | |
| Jan Smilek | M | 57 | 3 years | |
| Joseph G. Darling | M | 66 | 7 years | |
| Shi-Chung Ng | M | 69 | 11 years | |
| Luke Seikkula | M | 60 | 10 years | |
| Irene C. Kerr | F | 74 | 10 years | |
| Robert Karr | M | 75 |
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | 8 years |
| Timothy Ring | M | 66 | 10 years | |
| Gregory Deener | M | 62 | - | |
| H. Watkins | M | 71 | 19 years | |
| Robert E. Pelzer | M | 70 | 9 years | |
| Holger Liepmann | M | 72 | 25 years | |
| George F. Horner | M | 80 | 17 years | |
| John Walter | M | 76 | 17 years | |
| Gary P. Coughlan | M | 80 | 11 years | |
| Christopher Kuebler | M | 70 | 8 years | |
| Boone Powell | M | 87 | - | |
| Peter S. DiStefano | M | 66 | 5 years | |
| Eric Adams | M | 61 | 4 years | |
| Edward Michael | M | 66 | - | |
| John Leonard | M | 66 | 20 years | |
| Edward Fiorentino | M | 65 | - | |
| Mark Miller | M | 68 | 16 years | |
| Yat Sun Or | M | 72 | 14 years | |
| Paul Edick | M | 67 |
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | 8 years |
| Todd Davis | M | 63 | 5 years | |
| Guy MacDonald | M | 65 | 5 years | |
| Joy Amundson | F | 69 | 16 years | |
| Thomas O. Hecht | M | 73 |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 5 years |
| Susan Rodriguez | F | 60 | 24 years | |
| Thomas Ebeling | M | 65 | - | |
| Alan S. Rosenthal | M | - | 6 years | |
| Philippe G. Prokocimer | M | 74 | 7 years | |
| Christopher Begley | M | 71 | 18 years | |
| O. Ralph Edwards | M | 89 | - | |
| Paul D. Rubin | M | 70 | 6 years | |
| Jeffrey Stewart | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 97 | 97.00% |
| Switzerland | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James J. Egan
- Personal Network
